Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 4, 2004 - Issue 5
Submit an article Journal homepage
89
Views
27
CrossRef citations to date
0
Altmetric
Review

Magnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease

Lisa Mosconi New York University School of Medicine, Department of Psychiatry, Center for Brain Health, 560 First Avenue, NY 10016, USA. [email protected]
,
Susan De Santi New York University School of Medicine, Department of Psychiatry, Center for Brain Health, 560 First Avenue, NY 10016, USA. [email protected]
,
Henry Rusinek New York University BCD, Department of Radiology, 1 10, 462 First Avenue, NY 10016, USA. [email protected]
,
Antonio Convit New York University, Department of Psychiatry, School of Medicine, Nathan Kline Institute, Orangeburg, NY 10962, USA. [email protected]
&
Mony J de Leon New York University, Department of Psychiatry, School of Medicine, Nathan Kline Institute, Orangeburg, NY 10962, USA. [email protected]
Pages 831-849 | Published online: 10 Jan 2014

  • Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am j Public Health88, 1337–1342 (1998).
  • National Institute on Aging. Progress Report on Alzheimer's Disease. National Institute on Aging publication, Bethesda, MD, 96, 4137 (1996).
  • Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobial Aging 19, 109–116 (1998).
  • Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia, sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Gun. Positron Imaging 2, 119–130 (1999).
  • Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1143–1153 (2001).
  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arrb. Neural 56, 303–308 (1999).
  • Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 82,239–259 (1991).
  • ••Landmark paper showing the regional neuropathologic staging of neurofibrillary tangle (NFT) distribution in the brain.
  • Agdeppa ED, Kepe V, Petri A et al In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18) F] fluoroethyl)(methyl)amino1-2-naphthyll ethylidene)malononitrile. Neuroscience 117, 723–730 (2003).
  • Klunk WE, Engler H, Nordberg A et al Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neural 55, 306–319 (2004).
  • Silverman DH, Small GW, Chang CY et al Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. Am. Merl Assoc. 286, 2120–2127 (2001).
  • •Includes the largest series of histopathologically confirmed positron emission tomography (PET) scans from diverse degenerative disease patients.
  • Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neural. 2,605–613 (2003).
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neumlogy34, 939–944 (1984).
  • Ball MJ, Hachinski V, Fox A et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet5,14–16 (1985).
  • Amaral DG, Insausti R. Hippocampal formation. In: The Human Nervous System. Paxinos G (Ed.). Academic Press, Inc., CA, USA, 711–755 (1990).
  • Hyman BT, Van Hoesen GW, Damasio AR, BarnesCL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225,1168–1170 (1984).
  • Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobial Aging 12,295–312 (1991).
  • Arriagada PV, Marzloff K, Hyman BT Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42, 1681–1688 (1992).
  • Morris JC, McKeel DW, Storandt M et al. Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathological distinction from normal aging. Neurology 41, 469–478 (1991).
  • Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neural 60, 729–736 (2003).
  • Braak H, Braak E. Aspects of cortical destruction in Alzheimer's disease. In: Connections, cognition ancl Alzheimer,i disease. Hyman BT, Duyckaerts C, ChristenY (Eds). Springer-Verlag, Berlin, Germany, 1–16 (1997).
  • Hof PR, Giannakopoulos P, Bouras C. The neuropathological changes associated with normal brain aging. 1-listology Hstopathol 11, 1075–1088 (1996).
  • Naslund J, Haroutunian V, Mobs R et al Correlation between elevated levels of amyloid 0-peptide in the brain and cognitive decline. J. Am. Med. Assoc 283, 1571–1577 (2000).
  • Davies DC, Horwood N, Isaacs SL, Mann DMA. The effect of age and Alzheimer's disease on pyramidal neurone density in the individual fields of the hippocampal formation. Acta Neuropathologica. 83, 510–517 (1992).
  • Bobinski MJ, Wegiel J, Wisniewski HM et al Neurofibrillary pathology — correlation with hippocampal formation atrophy in Alzheimer's disease. Neurobial Aging17, 909–919 (1996).
  • Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Aburascience 16,4491–4500 (1996).
  • Bobinski M, de Leon MJ, Wegiel J et al The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95,721–725 (2000).
  • Jack CR Jr, Dickson DW, Parisi JE et al Ante mortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neumlogy58, 750–757 (2002).
  • Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neurone number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch. Neural. 58,1395-1402 (2001).
  • Kril JJ, Patel S, Harding AJ, Halliday GM. Neurone loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathologica 103,370–376 (2002).
  • Thal DR, Rub U, Schultz C et al Sequence of A3 -proteindeposition in the human medial temporal lobe. J. Neuropath. Exp. Neural. 59,733-748 (2000).
  • Hulette CM, Welsh-Bohmer IKA, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in 'normal' aging: evidence for preclinical Alzheimer's disease in cognitively normal individuals. J. Neuropath. Exp. Neural. 57,1168–1174 (1998).
  • Haroutunian V, Perl DP, Purohit DP et al Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch. Neural 55,1185–1191 (1998).
  • Adlard PA, Vickers JC. Morphologically distinct plaque types differentially affect dendritic structure and organisation in the early and late stages of Alzheimer's disease. Acta Neuropathologica 103,377–383 (2002).
  • Andreasen N, Minthon L, Vanmechelen E. Cerebrospinal fluid tau and A01-42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273,5-8 (1999).
  • Arai H, Ishiguro K, Ohna H etal. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neural. 166,201-203 (2000).
  • Vanmechelen E, Vanderstichele H, Davidsson P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285,49-52 (2000).
  • Hu YY, He SS, Wang X et al Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol 160, 1269–1278 (2002).
  • Buerger K, Teipel SJ, Zinkowski R et al CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627–629 (2002).
  • Buerger K, Zinkowski R, Teipel SJ et al Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Nemo'. 59,1267-1272 (2002).
  • Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297,353–356 (2002).
  • DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral antiAbeta antibody alters CNS and plasma A0 clearance and decreases brain A0 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci USA 98,8850–8855 (2001).
  • Jensen M, Schroder J, Blomberg M et al Cerebrospinal fluid A01-42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Nemo'. 45,504-511 (1999).
  • Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-A01_42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch. Neural 58,373–379 (2001).
  • Hulstaert F, Blennow K, Ivanoiu A et al Improved discrimination of AD patients using 0-amyloid (1–42) and tau levels in CSE Neurology52, 1555–1562 (1999).
  • Tapiola T, Pirttila T, Mildconen M et al Three-year follow-up of cerebrospinal fluid tau, P-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280, 119–122 (2000).
  • Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer's disease. Arch. Neural. 57, 100–105 (2000).
  • Silverberg GD, Levinthal E, Sullivan EV et al Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology59, 1139–1145 (2002).
  • Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid p 42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch. Neural. 55,937-945 (1998).
  • de Leon MJ, Ferris SH, Blau I et al. Correlations between computerized tomographic changes and behavioural deficits in senile dementia. Lancet 2, 859–860 (1979).
  • de Leon MJ, George AE, Ferris SH et al. Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNRAinJ Neuroradial 4,553–556 (1983).
  • DeCarli C, Haxby JV, Gillette JA, Teichberg D, Rapoport SI, Schapiro MB. Longitudinal changes in lateral ventricular volume in patients with dementia of the Alzheimer type. Aiumlogy 42, 2029–2036 (1992).
  • Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 348, 94–97 (1996).
  • Rusinek H, De Santi S, Frid D et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229,691–696 (2003).
  • ••First report that the rate of magneticresonance determined medial temporal lobe atrophy predicted the transition from normal cognition to mild cognitive impairment (MCI).
  • de Leon MJ, Bobinski M, Convit A, DeSanti S. Neuropatholgoical and neuroimaging studies of the hippocampus in normal aging and Alzheimer's disease. In: Neurobiology of .114ntal Illness Charney DS, Nestler EJ, Bunney BS (Eds). Oxford University Press, NY, USA, 698–714 (1999).
  • Smith AD. Imaging the progression of Alzheimer pathology through the brain. Proc. Natl Acad. Sc]. 9,4135–4137 (2002).
  • de Leon MJ, George AE, Golomb J et al Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neumbial Aging18,1–11 (1997).
  • Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch. Neural. 50,949–954 (1993).
  • Convit A, de Leon MJ, Tarshish C et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobial Aging18, 131–138 (1997).
  • Detoledo-Morrell L, Sullivan MP, Morrell F, Wilson RS, Bennett DA, Spencer S. Alzheimer's disease: in vivo detection of differential vulnerability of brain regions. Neurobial Aging18,463–468 (1997).
  • Jack CR Jr, Petersen RC, Xu YC et al Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49, 786–794 (1997).
  • De Sand S, deLeon MJ, Rusinek H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobial Aging22, 529–539 (2001).
  • •Only paper to date showing that hippocarnpus metabolism can differentiate MCI and Alzheimer's disease (AD) from normal aging.
  • Visser PJ, Scheltens,P, Verby FRJ et al Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J. Neural. 246,477–485 (1999).
  • Kohler S, Black SE, Sinden M et al Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer's disease. Neuropsychologia 36, 901–914 (1998).
  • Bobinski M, de Leon MJ, Convit A et al MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 353,38–40 (1999).
  • Juottonen K, Laakso MP, Insausti R et al Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobial Aging19, 15–22 (1998).
  • Herholz K. PET studies in dementia. Ann. Nucl. Med. 17,79–89 (2003).
  • Kessler RM. Imaging methods for evaluating brain function in man. Neurobiol S21—S35 (2003).
  • Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45,594–607 (2004).
  • Terry RD, Masliah E, Salmon DP et al Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neural. 30,572–580 (1991).
  • Ferris SH, de Leon MJ, Wolf AP et al. Positron emission tomography in the study of aging and senile dementia. Neurobial Aging1,127-131 (1980). First fluoro-2-deoxy-D-glucose (FDG)-PET study in AD, widespread neocortical reductions were observed.
  • Minoshima S, Giordani B, Berent S, Frey IKA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neural. 42,85–94 (1997).
  • ••Identified that posterior cingulate cortexhypometabolism predicts the conversion to AD.
  • de Leon MJ, Ferris SH, George AE et al Positron emission tomographic studies of aging and Alzheimer's disease. AJNR Am. J. Neuroradial 4,568–571 (1983).
  • Friedland R, Brun A, Budinger T Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1, 228 (1985).
  • Foster NL, Chase TN, Mansi et al. Cortical abnormalities in Alzheimer's disease. Ann. Neural. 16,649–654 (1984).
  • Frackowiak RSJ, Pozzilli C, Legg NJ et al Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104,753–778 (1981)
  • Herholz K, Salmon E, Perani D et al Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17,302–316 (2002).
  • Desgranges B, Baron JC, de la Sayette V et al. The neural substrates of memory systems impairment in Alzheimer's disease: a PET study of resting brain glucose utilization. Brain 121,611–631 (1998).
  • Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neural. 54,343–351 (2003).
  • de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 2,672–673 (1989).
  • •• First report that hippocarnpus atrophy predicts future conversion from MCI to AD. www.future-drugs.com
  • de Leon MJ, Golomb J, George AE et al The radiologic prediction of Alzheimer's disease: the atrophic hippocampal formation. AJNR Am. J Neuroradial 14, 897–906 (1993).
  • Kaye JA, Swihart T, Howieson D et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 48,1297–1304 (1997).
  • Jack CR Jr, Petersen RC, Xu YC et al Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology52,1397–1403 (1999).
  • Convit A, de Asis J, de Leon MJ, Tarshish C, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in nondemented elderly predict decline to Alzheimer's disease. Neumbial Aging21, 19–26 (2000).
  • Killiany RJ, Gomez-Isla T, Moss M et al Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neural 47,430–439 (2000).
  • Killiany RJ, Hyman BT, Gomez-Isla T= et al MRI measures of entorhinal cortex vs. hippocampus in preclinical AD. Neurology 58,1188–1196 (2002).
  • Jack CR Jr, Petersen RC, Xu Y, O'Brien PC et al Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology55,484–489 (2000).
  • Jack CR Jr, Shiung MM, Gunter JL et al Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology62,591–600 (2004).
  • Dickerson BC, Goncharova I, Sullivan MP et al MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobial Aging 22,747–754 (2001).
  • de Leon MJ, George AE, Golomb J et al Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neumbial Aging 18,1–11 (1997).
  • Minoshima S, Frey K, Koeppe R, Foster N, Kuhl D. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of flourine-18-FDG PET J. Nucl. Med. 36, 1238–1248 (1995).
  • Herholz K, Nordberg A, Salmon E et al Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement. Ceriatr Cogn. Disord. 10, 494–504 (1999).
  • Arnaiz E, Jelic V, Almkwist 0 et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12,851–855 (2001).
  • Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60, 1374–1377 (2003).
  • Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: A general linear approach. Hum. Brain. Mapping2, 189–210 (1995).
  • Drzezga A, Lautenschlager N, Siebner H et al Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J Nucl. Med. Mal Imaging 30,1104–1113 (2003).
  • de Leon MJ, Convit A, Wolf OT et al Prediction of cognitive decline in normal elderly subjects with 2-[(18)F1fluoro-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc. Natl Acad. Sc]. USA 98,10966–10971 (2001).
  • •First demonstration that FDG PET could be used to predict the transition from normal cognition to MCI.
  • Corder EH, Saunders AM, Strittmatter WJ et al Gene dose of apolipoprotein E Type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261,921–923 (1993).
  • Reiman EM, Uecker A, Caselli RJ et al Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann. Neural 44, 288–291 (1998).
  • Geroldi C, Pihlajamaki M, Looks° MP et al APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology53,1825–1832 (1999).
  • Small GW, Ercoli LM, Silverman DH et al Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Nati Acad. Sc]. USA 97, 6037–6042 (2000).
  • Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Nail Arad Sc]. USA 98,3334–3339 (2001).
  • Hirono N, Hashimoto M, Yasuda M et al. The effect of APOE E4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology58,743–750 (2002).
  • Mosconi L, Nacmias B, Sorbi S et al Brain metabolic decreases related to the dose of the APOE E4 allele in Alzheimer's disease. J Neural Neurosurg. PTchiatry75, 370–376 (2004).
  • Videen TO, Perlmutter JS, Mintun MA, Raichle ME. Regional correction of positron emission tomography data for effects of cerebral atrophy. I Cerebr. Blood Flow Metab. 8,662–670 (1988).
  • Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology47, 454–461 (1996).
  • Ibanez V, Pietrini P, Alexander GE et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology50,1585–1593 (1998).
  • Good CD, Scahill RI, Fox NC et al Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neumimage 17,29–46 (2002).
  • Johnson IKA, Jones K, Holman BL et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology50, 1563–1571 (1998).
  • Kogure D, Matsuda H, Ohnishi T et al Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl. Med 41,1155–1162 (2000).
  • Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521–529 (1999).
  • Perry RJ, Hodges JR. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology54, 2277–2284 (2000).
  • Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 57, 1756–1763 (2001).
  • Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants. J Nemo'. Neumsurg. Fiychiatry59, 61–70 (1995).
  • Ishii K, Sakamoto S, Sasaki M et al Cerebral glucose metabolism in patients with frontotemporal dementia. J. Nucl. Med. 39,1875–1878 (1998).
  • Boccardi M, Pennanen C, Laakso MP et al Amygdaloid atrophy in frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 335,139–13 (2002).
  • Galton CJ, Gomez-Anson B, Antoun N et al Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. J. Neural Neurosurg. fiychiatry70, 165–173 (2001).
  • Boxer AL, Rankin KP, Miller BL et al. Cinguloparietal atrophy distinguishes Alzheimer's disease from semantic dementia. Arch. Neural. 60,949–956 (2003).
  • Varma AR, Adams W, Lloyd JJ et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia. Acta Neural. Scand.105, 261–269 (2002).
  • Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54,1304–1309 (2000).
  • Burton EJ, Karas G, Paling SM et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Aimaimage 17,618–630 (2002).
  • Cousins DA, Burton EJ, Bum D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology61, 1191–1195 (2003).
  • Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. int. J. Cellar': fiychiatry15,911–916 (2000).
  • O'Brien JT, Paling S, Barber R et al., Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology56, 1386–1388 (2001).
  • Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology52, 1153–1158 (1999).
  • Albin RL, Minoshima S, D'Amato CJ, Frey IKA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology47,462–466 (1996).
  • Minoshima S, Foster NL, Sima AA, Frey IKA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neural. 50,358–365 (2001).
  • Gerlach M, Stadler K, Aichner F, Ransmayr G. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology59,1476 (2002).
  • O'Brien JT, Desmond P, Ames D, Schweitzer I, Chiu E, Tress B. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. Psycho" Med. 27,1267-1275 (1997).
  • Szelies B, Mielke R, Herholz K, Heiss WD. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogc Cli. Neurophysiol 91, 131–139 (1994).
  • O'Brien JT, Desmond P, Ames D, Schweitzer I, Tuckwell V, Tress B. The differentiation of depression from dementia by temporal lobe magnetic resonance imaging. Bychol. Med. 24(3), 633–640 (1994).
  • Pantel J, Schroder J, Essig M et al. Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. J. Affect. Disond 42, 69–83 (1997).
  • Sheline YT, Wang PW, Gado MET, Csemansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sci. USA 93, 3908–3913 (1996).
  • Ballmaier M, Sowell ER, Thompson PM et al Mapping brain size and cortical gray matter changes in elderly depression. Biol. PTchiatry55,382–389 (2004).
  • Guze BH, Baxter LR Jr, Schwartz JM, Szuba MP, Mazziotta JC, Phelps ME. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report. Psychiatry Res. 40,195–202 (1991).
  • Ebmeier IKP, Prentice N, Ryman A et al Temporal lobe abnormalities in dementia and depression: a study using high resolution single photon emission tomography and magnetic resonance imaging. .1. Neural. Neurosurg. Psychiatry63, 597–604 (1997).
  • Ebmeier IKP, Glabus ME, Prentice N, Ryman A, Goodwin GM. A voxel-based analysis of cerebral perfusion in dementia and depression of old age. Neuroimage 7, 199–208 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.